References
- D. Tomasoni, M. Adamo M, C.M. Lombardi, M. Metra, “Highlights in heart failure”, ESC Heart Fail, vol. 6 no. 6, pp. 1105–1127, Dec 2019. doi: 10.1002/ehf2.12555 PMID: 31997538 PMCID: PMC6989277
- D. Tomasoni, M. Adamo, M.S. Anker, S. von Haehling, A.J.S. Coats, M. Metra, “Heart failure in the last year: progress and perspective”, ESC Heart Fail, vol. 7 no. 6, pp. 3505–3530, 2020. doi: 10.1002/ehf2.13124 PMID: 33277825 PMCID: PMC7754751
- L. Stretti, D. Zippo, A.J.S. Coats, M.S. Anker, S. von Haehling, M. Metra, D. Tomasoni “A year in heart failure: an update of recent findings”, ESC Heart Fail, vol. 8 no. 6, pp. 4370–4393, December 2021. doi: 10.1002/ehf2.13760 PMID: 34918477 PMCID: PMC9073717
- T.A. McDonagh, M. Metra, M.Adamo, R.S. Gardner, A. Baumbach, M. Böhm, H. Burri, J. Butler, J. Čelutkienė, O. Chioncel, et al., “2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC”, Eur. Heart J., 42, pp. 3599–3726, 2021.
- A.N. Emara, N.O. Mansour, M.H. Elnaem, M. Wadie, I.S. Dehele, M.E.E. Shams, “Efficacy of Nondiuretic Pharmacotherapy for Improving the Treatment of Congestion in Patients with Acute Heart Failure: A Systematic Review of Randomised Controlled Trials”, J Clin Med., vol. 11 no. 11, p. 3112, May 2022. doi: 10.3390/jcm11113112 PMID: 35683505 PMCID: PMC9181246
- A. Cahn, O. Mosenzon, S.D. Wiviott, A. Rozenberg, I. Yanuv, E.L. Goodrich, S.A. Murphy, D.L. Bhatt, L.A. Leiter, D.K. McGuire, J.P.H. Wilding, I.A.M. Gause-Nilsson, M. Fredriksson, P.A. Johansson, A.M. Langkilde, M.S. Sabatine, I. Raz, “Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study”, Diabetes Care, vol. 43 no. 2, pp. 468–475, December 2019. doi: 10.2337/dc19-1476. Epub 2019 Dec 16. PMID: 31843945.
- L.M. Pérez-Belmonte, J. Sanz-Cánovas, M. Millán-Gómez, J. Osuna-Sánchez, A. López-Sampalo, M. Ricci, M. Jiménez-Navarro, M.D. López-Carmona, M.R. Bernal-López, M.A. Barbancho, J.P. Lara, R. Gómez-Huelgas, “Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure”, J Am Geriatr Soc., vol. 70 no. 3, pp. 862–871, November 2021. doi: 10.1111/jgs.17585 PMID: 34843628
- F. Ilyas, L. Jones, S.L. Tee, M. Horsfall, A. Swan, F. Wollaston, T. Hecker, C. De Pasquale, S. Thomas, W. Chong, S. Stranks, A.A. Mangoni, J.B. Selvanayagam, D.P. Chew, C.G. De Pasquale. “Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial”, ESC Heart Fail., vol. 8 no. 5, pp. 4346–4352, August 2021. doi: 10.1002/ehf2.13553 PMID: 34382353 PMCID: PMC8497349
- D. Kolijn, S, Pabel, Y. Tian, M. Lódi, M. Herwig, A. Carrizzo, S. Zhazykbayeva, Á. Kovács, G.Á. Fülöp, I. Falcão-Pires, P.H. Reusch, S.V. Linthout, Z. Papp, L. van Heerebeek, C. Vecchione, L.S. Maier, M. Ciccarelli, C. Tschöpe, A. Mügge, Z. Bagi, S. Sossalla, N. Hamdani, “Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation”, Cardiovasc Res., vol. 117 no. 2, pp. 495–507, January 2021. doi: 10.1093/cvr/cvaa123 PMID: 32396609
- T. Koufakis, O.G. Mustafa, R.A. Ajjan, X. Garcia-Moll, P. Zebekakis, G. Dimitriadis, K. Kotsa, “From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients”, Drugs, vol. 82 no. 9 pp. 949–955, June 2022. doi: 10.1007/s40265-022-01730-2 PMID: 35678922 PMCID: PMC9178534
- A. Groenewegen, F.H. Rutten, “Sodium-glucose co-transporter 2 inhibitors and acute heart failure”, Eur J Heart Fail, vol. 2 no. 4, pp. 723–725, April 2020. doi: 10.1002/ejhf.1759 PMID: 32072715
- K. Thiele, M. Rau, N.K. Hartmann, M. Möller, J. Möllmann, J. Jankowski, A.P. Keszei, M. Böhm, J. Floege, N. Marx, M. Lehrke, “Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure”, ESC Heart Fail, vol. 9 no. 4, pp. 2233–2238, May 2022. doi: 10.1002/ehf2.13955. PMID: 35611683 PMCID: PMC9288802
- V. Rotbain Curovic, M.B. Houlind, T.W. Hansen, J. Eugen-Olsen, J.C. Laursen, M.K. Eickhoff, F. Persson, P. Rossing, “Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor”, Front Pharmacol, 27, 13, 799915, April 2022. doi: 10.3389/fphar.2022.799915 PMID: 35571091 PMCID: PMC9091812
- G. Savarese, N. Sattar, J. Januzzi, S. Verma, L.H. Lund, D. Fitchett, C. Zeller, J.T. George, M. Brueckmann, A.P. Ofstad, S.E. Inzucchi, C. Wanner, B. Zinman, J. Butler, “Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality”, Circulation, vol. 139, no. 11, pp. 1458–1460, March 2019. doi: 10.1161/CIRCULATIONAHA.118.038339 PMID: 30855996
- D.L. Bhatt, M. Szarek, P.G. Steg, C.P. Cannon, L.A. Leiter, D.K. McGuire, J.B. Lewis, M.C. Riddle, A.A. Voors, M. Metra, L.H. Lund, M. Komajda, J.M. Testani, C.S. Wilcox, P. Ponikowski, R.D. Lopes, S. Verma, P. Lapuerta, B. Pitt, “SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure”, N Engl J Med, vol. 384 no. 2, pp.117–128, Jan 2021. doi: 10.1056/NEJMoa2030183 PMID: 33200892
- A.A. Voors, C.E. Angermann, J.R. Teerlink, S.P. Collins, M. Kosiborod, J. Biegus, J.P. Ferreira, M.E. Nassif, M.A. Psotka, J. Tromp, C.J.W. Borleffs, C. Ma, J. Comin-Colet, M. Fu, S.P. Janssens, R.G. Kiss, R.J. Mentz, Y. Sakata, H. Schirmer, M. Schou, P.C. Schulze, L. Spinarova, M. Volterrani, J.K. Wranicz, U. Zeymer, S. Zieroth, M. Brueckmann, J.P. Blatchford, A. Salsali, P. Ponikowski, “The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial”, Nat Med, vol. 28 no. 3, pp. 568–574, February 2022. doi: 10.1038/s41591-021-01659-1 PMID: 35228754 PMCID: PMC8938265
- M.N. Kosiborod, C.E. Angermann, S.P. Collins, J.R. Teerlink, P. Ponikowski, J. Biegus, J. Comin-Colet, J.P. Ferreira, R.J. Mentz, M.E. Nassif, M.A. Psotka, J. Tromp, M. Brueckmann, J.P. Blatchford, A. Salsali, A.A. Voors, “Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial”, vol. 146 no. 4, pp. 279–288, April 2022. doi: 10.1161/CIRCULATIONAHA.122.059725 PMID: 35377706 PMCID: PMC9311476
- S. Tamaki, T. Yamada, T. Watanabe, T. Morita, Y. Furukawa, M. Kawasaki, A. Kikuchi, T. Kawai, M. Seo, M. Abe, J. Nakamura, K. Yamamoto, K. Kayama, M. Kawahira, K. Tanabe, K. Fujikawa, M. Hata, Y. Fujita, Y. Umayahara, S. Taniuchi, S. Sanada, A. Shintani, M. Fukunami, “Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study”, Circ Heart Fail, vol. 14 no. 3, March 2021. doi: 10.1161/CIRCHEARTFAILURE.120.007048. Erratum in: Circ Heart Fail, vol. 14 no. 4, April 2021. PMID: 33663235
- E.M. Boorsma, J.C. Beusekamp, J.M. Ter Maaten, S.M. Figarska, A.H.J. Danser, D.J. van Veldhuisen, P. van der Meer, H.J.L. Heerspink, K. Damman, A.A. Voors, “Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure”, Eur J Heart Fail, vol. 23 no. 1, pp. 68–78, Dec 2020. doi: 10.1002/ejhf.2066 PMID: 33251643 PMCID: PMC8048437
- K. Damman, J.C. Beusekamp, E.M. Boorsma, H.P. Swart, T.D.J. Smilde, A. Elvan, J.W.M. van Eck, H.J.L. Heerspink, A.A. Voors, “Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)”, Eur J Heart Fail, vol. 22 no. 4, pp. 713–722, Jan 2020. doi: 10.1002/ejhf.1713 PMID: 31912605
- K.M. Hallow, G. Helmlinger, P.J. Greasley, J.J.V. McMurray, D.W. Boulton, “Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis”, Diabetes Obes Metab, vol. 20 no. 3, pp. 479–487, Nov 2017. doi: 10.1111/dom.13126 PMID: 29024278
- K. Charaya, D. Shchekochikhin, D. Andreev, I. Dyachuk, S. Tarasenko, M. Poltavskaya, D. Mesitskaya, A. Bogdanova, N. Ananicheva, A. Kuzub, “Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study”, Open Heart, vol. 9 no. 1, May 2022. doi: 10.1136/openhrt-2021-001936 PMID: 35609943; PMCID: PMC9131063
- B.J. Kraus, M.R. Weir, G.L. Bakris, M. Mattheus, D.Z.I. Cherney, N. Sattar, H.J.L. Heerspink, I. Ritter, M. von Eynatten, B. Zinman, S.E. Inzucchi, C. Wanner, A. Koitka-Weber, “Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial”, Kidney Int, vol. 99 no. 3, pp. 750–762, Mar 2021. doi: 10.1016/j.kint.2020.10.031 PMID: 33181154
- L.M. Pérez-Belmonte, M. Ricci, J. Sanz-Cánovas, M. Millán-Gómez, J. Osuna-Sánchez, M.I. Ruiz-Moreno, M.R. Bernal-López, M.D. López-Carmona, M. Jiménez-Navarro, J.J. Gómez-Doblas, J.P. Lara, R. Gómez-Huelgas, “Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure”, J Clin Med, vol. 10 no. 16, p. 3540, August 2021. doi: 10.3390/jcm10163540 PMID: 34441835 PMCID: PMC8396978
- R.H.M. Furtado, I. Raz, E.L. Goodrich, S.A. Murphy, D.L. Bhatt, L.A. Leiter, D.K. McGuire, J.P.H. Wilding, P. Aylward, A.J. Dalby, M. Dellborg, D. Dimulescu, J.C. Nicolau, A.J.M. Oude Ophuis, A. Cahn, O. Mosenzon, I. Gause-Nilsson, A.M. Langkilde, M.S. Sabatine, S.D. Wiviott, “Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial”, vol. 145 no. 21, pp. 1581–1591, May 2022. doi: 10.1161/CIRCULATIONAHA.121.058103 PMID: 35510542.
- Kosiborod et al., “Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial”, Lancet Diabetes Endocrinol, vol. 9, pp. 586–94, 2021.
- Z.L. Cox, S.P. Collins, M. Aaron, G.A. Hernandez, A.T.M. Iii, B.T. Davidson, M. Fowler, C.J. Lindsell, F.E.H. Jr, C.A. Jenkins, C. Kampe, K.F. Miller, W.B. Stubblefield, J. Lindenfeld, “Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial”, Am Heart J, 232, pp. 116–124, Feb 2021. doi: 10.1016/j.ahj.2020.10.071 PMID: 33144086
- D. von Lewinski, M. Benedikt, N. Tripolt, M. Wallner, H. Sourij, E. Kolesnik, “Can sodium-glucose cotransporter 2 inhibitors be beneficial in patients with acute myocardial infarction?”, Kardiol Pol, vol. 79 no. 5, pp.503–509, 2021. doi: 10.33963/KP.15969 PMID: 34125922
- L. Cavka, U. Bencak Ferko, N. Pitz, Z. Trpkovski, M. Lainscak, “Sodium-glucose cotransporter 2 inhibitor-induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction”, ESC Heart Fail, vol. 8 no. 4, pp. 2631–2636, August 2021. doi: 10.1002/ehf2.13452 PMID: 34102028 PMCID: PMC8318418
- R. Wachter, M. Senni, J. Belohlavek, E. Straburzynska-Migaj, K.K. Witte, Z. Kobalava, C. Fonseca, E. Goncalvesova, Y. Cavusoglu, A. Fernandez, S. Chaaban, E. Bøhmer, A.C. Pouleur, C. Mueller, C. Tribouilloy, E. Lonn, J. A.L. Buraiki, J. Gniot, M. Mozheiko, M. Lelonek, A. Noè, H. Schwende, W. Bao, D. Butylin, D. Pascual-Figal, “TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study”, Eur J Heart Fail., vol. 21 no. 8, pp. 998–1007, August 2019. doi: 10.1002/ejhf.1498 PMID: 31134724
- E.J. Velazquez, D.A. Morrow, A.D. DeVore, C.I. Duffy, A.P. Ambrosy, K. McCague, R. Rocha, E. Braunwald, “PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure”, N Engl J Med, vol. 380 no. 6, pp. 539–548, Feb 2019. doi: 10.1056/NEJMoa1812851 Erratum in: N Engl J Med. vol. 380 no. 11, p. 1090, March 2019. PMID: 30415601
- D.Y. Chen, C.C. Chen, C.N. Tseng, S.W. Chen, S.H. Chang, W.K. Huang, M.S. Wen, M.J. Hsieh, I.C. Hsieh, “Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study”, EClinicalMedicine, 8;41:101149, Oct 2021. doi: 10.1016/j.eclinm.2021.101149 PMID: 34693232 PMCID: PMC8515399
- T. Martyn et al., “Acute Hemodynamic Effects of Sacubitril-Valsartan In Heart Failure Patients Receiving Intravenous Vasodilator and Inotropic Therapy”, J Card Fail, vol. 27 no. 3, pp. 368–372, March 2021.
- J.S. Tran, O. Havakuk, J.M. McLeod, J. Hwang, H.Y. Kwong, D. Shavelle, M.R. Zile, U. Elkayam, M.W. Fong, L.P. Grazette, “Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction”, ESC Heart Fail, vol. 8 no. 2, pp. 1706–1710, April 2021. doi: 10.1002/ehf2.13225 PMID: 33522140 PMCID: PMC8006690
- M.A. Pfeffer et al., “Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction”, N Engl J Med, 385, pp. 1845–1855, 2021. doi: 10.1056/NEJMoa2104508
- D. Carballo, J. Stirnemann, N. Garin, C. Marti, J. Serratrice, S. Carballo, “Eligibility for sacubitril-valsartan in patients with acute decompensated heart failure”, ESC Heart Fail, vol. 7 no. 3, pp. 1282–1290, March 2020. doi: 10.1002/ehf2.12676 PMID: 32167679 PMCID: PMC7261587
- S. Carballo, J. Stirnemann, N. Garin, P. Darbellay Farhoumand, J. Serratrice, D. Carballo, “Prognosis of patients eligible for dapagliflozin in acute heart failure”, Eur J Clin Invest, vol. 50 no. 6, June 2020. doi: 10.1111/eci.13245 PMID: 32306388
- M. Fudim, S. Sayeed, H. Xu, R.A. Matsouaka, P.A. Heidenreich, E.J. Velazquez, C.W. Yancy, G.C. Fonarow, A.F. Hernandez, A.D. DeVore, “Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction”, Circ Heart Fail., vol. 13 no. 4, April 2020. doi: 10.1161/CIRCHEARTFAILURE.119.006645 PMID: 32248695 PMCID: PMC8819257
- H. Kurdi, P. Shah, S. Barker, D. Harris, B. Dicken, C. Edwards, G. Jenkins, “Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure”, Br J Cardiol, vol. 28 no. 2, April 2021. doi: 10.5837/bjc.2021.018 PMID: 35747454 PMCID: PMC8822528
- N.S. Bassi, B. Ziaeian, C.W. Yancy, G.C. Fonarow, “Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure. JAMA Cardiol”, vol. 5 no. 8, pp. 948–951, Aug 2020. doi: 10.1001/jamacardio.2020.0898 PMID: 32374344 PMCID: PMC7203666
- A. Ntalianis, C. Chrysohoou, G. Giannakoulas, G. Giamouzis, A. Karavidas, A. Naka, C.H. Papadopoulos, S. Patsilinakos, J. Parissis, D. Tziakas, J. Kanakakis, “Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper”, Heart Fail Rev, vol. 27 no. 1, pp. 1–13, May 2021. doi: 10.1007/s10741-021-10115-8 PMID: 33931815 PMCID: PMC8087533
- D. Tomasoni, G.C. Fonarow, M. Adamo, S.D. Anker, J. Butler, A.J.S. Coats, G. Filippatos, S.J. Greene, T.A. McDonagh, P. Ponikowski, G. Rosano, P. Seferovic, M. Vaduganathan, A.A. Voors, M. Metra, “Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction”, Eur J Heart Fail, vol. 24, no. 3, pp. 431–441, March 2022. doi: 10.1002/ejhf.2397 PMID: 34894038; PMCID: PMC9303969
- A. Tymińska, K. Ozierański, M. Grabowski, G. Opolski, P. Balsam, “Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure”, Cardiol J, vol. 27 no. 5, pp. 625–632, 2020. doi: 10.5603/CJ.a2020.0094 PMID: 32648251 PMCID: PMC8078992
- E. Gayat, M. Arrigo, S. Littnerova, N. Sato, J. Parenica, S. Ishihara, J. Spinar, C. Muller, V.P. Harjola, J. Lassus, O. Miro, A.P. Maggioni, K.F. AlHabib, D.J. Choi, J.J. Park, Y. Zhang, J. Zhang, J.L. Januzzi, K. Kajimoto Jr., A. Cohen-Solal, A. Mebazaa, G. Network, “Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study”, Eur J Heart Fail 20:345354, 2018.
- J.J.V. McMurray, S.D. Solomon, S.E. Inzucchi, L. Køber, M.N. Kosiborod, F.A. Martinez, P. Ponikowski, M.S. Sabatine, I.S. Anand, J. Belohlavek, M. Böhm, C-E Chiang, V.K. Chopra, R.A. de Boer, A.S. Desai, M. Diez, J. Drozdz, A. Dukat, J. Ge, J.G. Howlett, T. Katova, M. Kitakaze, C.E.A. Ljungman, B. Merkely, J.C. Nicolau, E. O’Meara, M.C. Petrie, P.N. Vinh, M. Schou, S. Tereshchenko, S. Verma, C. Held, D.L. DeMets, K.F. Docherty, P.D. Jhund, O. Bengtsson, M. Sjöstrand, A.M. Langkilde, DAPA-HF Trial Committees and Investigators, “Dapagliflozin in patients with heart failure and reduced ejection fraction”, N Engl J Med, 2019. 381:19952008.
- S. Yusuf, M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J. McMurray, E.L. Michelson, B. Olofsson, J. Ostergren, CHARM Investigators and Committees, “Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial”, Lancet, 2003. 362:777781
- B. Pitt, M.A. Pfeffer, S.F. Assmann, R. Boineau, I.S. Anand, B. Claggett, N. Clausell, A.S. Desai, R. Diaz, J.L. Fleg, I. Gordeev, B. Harty, J.F. Heitner, C.T. Kenwood, E.F. Lewis, E. O’Meara, J.L. Probstfield, T. Shaburishvili, S.J. Shah, S.D. Solomon, N.K. Sweitzer, S. Yang, S.M. McKinlay, TOPCAT Investigators, “Spironolactone for heart failure with preserved ejection fraction”, N Engl J Med, 2014. 370:13831392.
- S.D. Solomon, J.J.V. McMurray, I.S. Anand, J. Ge, C.S.P. Lam, A.P. Maggioni, F. Martinez, M. Packer, M.A. Pfeffer, B. Pieske, M.M. Redfield, J.L. Rouleau, D.J. van Veldhuisen, F. Zannad, M.R. Zile, A.S. Desai, B. Claggett, P.S. Jhund, S.A. Boytsov, J. Comin-Colet, J. Cleland, H.D. Dungen, E. Goncalvesova, T. Katova, J.F. Kerr Saraiva, M. Lelonek, B. Merkely, M. Senni, S.J. Shah, J. Zhou, A.R. Rizkala, J. Gong, V.C. Shi, M.P. Lefkowitz, PARAGON-HF Investigators and Committees, “Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction”, N Engl J Med, 2019. 381:16091620